- Home
- PHVS vs OCSL Comparison
PHVS vs OCSL Comparison
Compare PHVS & OCSL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHVS
- OCSL
- Stock Information
- Founded
- PHVS 2015
- OCSL 2007
- Country
- PHVS Switzerland
- OCSL United States
- Employees
- PHVS N/A
- OCSL N/A
- Industry
- PHVS Biotechnology: Pharmaceutical Preparations
- OCSL Finance: Consumer Services
- Sector
- PHVS Health Care
- OCSL Finance
- Exchange
- PHVS Nasdaq
- OCSL Nasdaq
- Market Cap
- PHVS 1.3B
- OCSL 1.2B
- IPO Year
- PHVS 2021
- OCSL 2008
- Fundamental
- Price
- PHVS $24.30
- OCSL $13.41
- Analyst Decision
- PHVS Strong Buy
- OCSL Hold
- Analyst Count
- PHVS 5
- OCSL 6
- Target Price
- PHVS $35.60
- OCSL $15.20
- AVG Volume (30 Days)
- PHVS 123.2K
- OCSL 492.3K
- Earning Date
- PHVS 11-12-2025
- OCSL 08-05-2025
- Dividend Yield
- PHVS N/A
- OCSL 11.93%
- EPS Growth
- PHVS N/A
- OCSL N/A
- EPS
- PHVS N/A
- OCSL 0.55
- Revenue
- PHVS N/A
- OCSL $334,099,000.00
- Revenue This Year
- PHVS N/A
- OCSL N/A
- Revenue Next Year
- PHVS N/A
- OCSL N/A
- P/E Ratio
- PHVS N/A
- OCSL $24.53
- Revenue Growth
- PHVS N/A
- OCSL N/A
- 52 Week Low
- PHVS $11.51
- OCSL $12.50
- 52 Week High
- PHVS $26.33
- OCSL $16.66
- Technical
- Relative Strength Index (RSI)
- PHVS 59.77
- OCSL 40.18
- Support Level
- PHVS $23.20
- OCSL $13.11
- Resistance Level
- PHVS $24.75
- OCSL $13.65
- Average True Range (ATR)
- PHVS 1.29
- OCSL 0.18
- MACD
- PHVS 0.07
- OCSL -0.05
- Stochastic Oscillator
- PHVS 84.81
- OCSL 31.72
About PHVS Pharvaris N.V.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.
About OCSL Oaktree Specialty Lending Corporation
Oaktree Specialty Lending Corp is a specialty finance company. The company provides lending services and invests in small and mid-sized companies. The company's investment objective is to maximize its portfolio's total return by generating current income from debt investments, and to a lesser extent, capital appreciation from equity investments. The company provides customized, one-stop credit solutions to companies with limited access to public or syndicated capital markets.